Based on the above clinical trials results, we sought to perform a systematic assessment to verify whether the intercalated combination of chemotherapy and EGFR TKIs is superior to chemotherapy alone or EGFR TKIs alone in the treatment of NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.